Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8 mL dose.

The health secretary is planning to remove members of a panel that recommends vaccines if he sees conflicts of interest.

18, 2025 – The FDA has approved a new 5-in-1 shot to ... Sold as Penmenvy, it combines the active ingredients of two previously approved vaccines, offering better protection with fewer shots ...

Over the last 30 days, 151 flocks have been confirmed to have avian flu, affecting more than 23 million birds, according to ...

HHS Secretary Robert F. Kennedy Jr. plans to axe members of the department’s vaccine-centric panels of outside advisers who he deems to be too cozy with the drug industry.

The FDA has approved Bavarian Nordic’s Vimkunya, the first virus-like particle (VLP) chikungunya vaccine for patients over 12 years of age. According to the company, approval was based on strong ...